Trainings and Resources
13 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/17/2020 (updated 9/2/2021)
Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%–22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.
Posted 5/22/2020 (updated 9/2/2021)
Benzodiazepines, which are associated with safety-related harms for older adults, were not covered when the US Medicare Part D prescription drug benefit began. Coverage wasextended to benzodiazepines in 2013.
Posted 12/16/2020 (updated 9/2/2021)
Most fatal overdoses in the U.S. are opioid related, but also involve and other illicit substances. A new social determinant-based Community Health Needs Assessment tool applies a substance use journey, endemic prevalence, data source ideas, and program prioritization methods.
Posted 2/3/2021 (updated 9/2/2021)
The opioid crisis continues to exact a heavy toll on the United States, and overdose deaths have only increased during the current global pandemic. One effective intervention to reduce overdose deaths is to distribute the opioid antagonist naloxone directly to persons actively using opioids (ie, “take-home naloxone”), especially at touchpoints with the potential for significant impact such as emergency departments and jails. reliable funding for a naloxone supply. In this commentary, we establish the argument for a publicly funded naloxone supply to support take-home naloxone distribution in emergency department settings. We posit that the complex billing and reimbursement system for medication dispensing is impossibly burdensome during emergency care for an acute opioid overdose, and that the mounting death toll from this public health crisis demands a strong commitment to harm reduction.
Posted 4/7/2021 (updated 9/2/2021)
The U.S. Government Accountability Office (GAO) recently published their Drug Misuse report to the Congressional Committees, which stemmed from a provision in the Comprehensive Addiction and Recovery Act of 2016 (CARA) requiring GAO to review Good Samaritan and Naloxone Access Laws. GAO examined which states and territories have Good Samaritan and Naloxone Access laws, the effects of Good Samaritan laws, and the efforts the Office of National Drug Control Policy (ONDCP) has taken to disseminate information on Good Samaritan and Naloxone Access laws. GAO found that 47 states and D.C. have enacted both Good Samaritan and Naloxone Access laws, Kansas, Texas and Wyoming only have Naloxone Access laws, and five U.S. territories do not have any Good Samaritan or Naloxone Access laws in place. They also conducted literature reviews of studies examining the laws’ effectiveness and ONCDP documents and found that, while there were lower rates of overdose deaths in states with Good Samaritan laws, awareness of Good Samaritan laws varied across states and territories.
Posted 4/21/2021 (updated 9/2/2021)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 8/11/2021 (updated 9/2/2021)
The Office of the Assistant Secretary for Planning and Evaluation (ASPE) contracted with RTI International to conduct a scoping review of the scientific literature on non-fatal opioidinvolved overdose (NFOO) to better understand the health outcomes and health care implications associated with opioid epidemic. NFOO is a significant cause of opioid-related morbidity in the United States, and is of heightened interest to ASPE given the sharp increase in fatal and nonfatal opioid overdoses as a result of the current fentanyl crisis. Compared to the first and second phases of the opioid epidemic, when the majority of opioid-related morbidity and mortality was associated first with prescription opioids and then with heroin, illicitly-manufactured fentanyl (IMF) is now the leading cause of fatal opioid overdoses (CDC, 2017; O’Donnell, Gladden, & Seth, 2017). People who consume IMF, either wittingly or unwittingly, are at higher risk for accidental overdose, experience comparatively atypical overdose-related side effects, have unique risk profiles, and are at higher risk for poorer health outcomes (Somerville, 2017). To our knowledge, no investigation has been conducted to examine whether the sharp increase in NFOOs over the last several decades is negatively impacting overdose victims’ chronic physical and mental health outcomes. To investigate the status of the scientific literature regarding the consequences of NFOO on victims’ physical and mental health, we conducted a scoping review of the existing knowledge in multiple stages: (1) publication identification; (2) selection of publications; and (3) data extraction, charting, and synthesis. Key findings from our review are presented below.
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 4/20/2022 (updated 5/6/2022)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 3/24/2022 (updated 8/17/2022)
If you received specific disposal instructions from your healthcare provider (e.g., doctor, pharmacist) for your unused or expired medicine, you should follow those instructions to dispose of your medicine. The best disposal option is to find a drug take back location, which may be found in retail, hospital, or clinic pharmacies; and/or law enforcement facilities.